COMMUNIQUÉS West-GlobeNewswire
-
Arvinas and Pfizer Announce Initial Phase 1b Data from the TACTIVE-U Sub-Study of Vepdegestrant in Combination with Abemaciclib at 2024 San Antonio Breast Cancer Symposium
10/12/2024 -
Visory Health Joins Fast Company's Esteemed 2024 Brands That Matter List
10/12/2024 -
Zealand Pharma announces first participant enrolled in Phase 2b ZUPREME-1 trial of petrelintide in people with overweight or obesity
10/12/2024 -
Longer-term Novartis Kisqali® NATALEE data show durable reduction in distant recurrence in broad population of patients with early breast cancer
10/12/2024 -
H1 Partners with CTI to Streamline Clinical Trial PI and Site Selection for More Inclusive and Efficient Trials
10/12/2024 -
ACC Medlink Highlights Commitment to Excellence in Patient Care at ACMA Case Management Conference
10/12/2024 -
Roche commences tender offer for all shares of Poseida Therapeutics, Inc. for $9.00 per share in cash, plus a non-tradeable contingent value right for up to $4.00 per share in cash
09/12/2024 -
Verrica Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
09/12/2024 -
NANOBIOTIX Announces Completion of Phase 1 Study of NBTXR3 (JNJ-1900) in Pancreatic Cancer
09/12/2024 -
NANOBIOTIX annonce l’achèvement de l’étude de phase 1 avec NBTXR3 (JNJ-1900) dans le cancer du pancréas
09/12/2024 -
Krystal Biotech Provides Update on EMA’s Ongoing Regulatory Review of B-VEC for Dystrophic Epidermolysis Bullosa
09/12/2024 -
Relay Therapeutics to Present Updated Clinical Data on RLY-2608 in HR+/HER2- Breast Cancer at 2024 San Antonio Breast Cancer Symposium
09/12/2024 -
Oncocyte to Participate in “J.P. Morgan Week” and Host Investor Meetings
09/12/2024 -
Myriad Genetics to Present New Data at San Antonio Breast Cancer Symposium
09/12/2024 -
LENSAR Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
09/12/2024 -
Fate Therapeutics Presents New Phase 1 Clinical Data of FT819 Off-the-shelf, CAR T-cell Product Candidate for Systemic Lupus Erythematosus
09/12/2024 -
Chimerix to Submit Dordaviprone for Accelerated Approval to U.S. FDA for Patients with Recurrent H3 K27M-Mutant Diffuse Glioma Before Year-End
09/12/2024 -
Biomea Fusion Announces Preliminary Data from Ongoing COVALENT-103 Study of Investigational Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia
09/12/2024 -
Protara Announces Proposed Public Offering
09/12/2024
Pages